NEW YORK (PRWEB)
August 24, 2022

Betterbrand recently added a new product to their respiratory and immune health supplements lineup: BetterLungs® Immunity with IMMUSE™ that rolled out in 1,000+ CVS stores nationwide. This first-ever respiratory gummy to feature IMMUSE™ was designed to support respiratory health; help reduce fatigue from exercise; provide clinically researched, year-round immune support; and help with work productivity by supporting the immune system.*

Developed by Dr. Chris Jackson, Pharm.D, Betterbrand was the culmination of years of research and planning to help everyone live a better and more balanced life through natural, effective products. “Watching my grandma struggle with respiratory issues drove me to want to help the millions of others suffering with the same health issues,” said Dr. Chris. “However, in pharmacy school I realized there was an enormous opportunity to change lives through education and empowerment beyond respiratory support.”

Before incorporating it into their product, Betterbrand put IMMUSE™ through a rigorous process of consideration that is standard at the company. They thoroughly researched IMMUSE™, cross-referencing its claims with current scientific research to vouch for its safety, function, and potential interactions. They also ensured quality at the production source, iterated different ingredient ratios before settling on an optimal formulation, and tested their final product with a third-party lab.

“Supporting immune system health is more important than ever, and we are pleased to see our IMMUSE™ ingredient formulated into a Betterbrand product, knowing the care and attention paid to bringing this innovative formulation to market,” commented Karen Todd, MBA, RD, Vice President Global Brand Marketing, Kyowa Hakko USA, Inc.

Each daily BetterLungs® Immunity with IMMUSE™ gummy contains 50 mg of IMMUSE™ LC-plasma, a postbiotic that proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*.

IMMUSE™ is backed by 29 published studies, including 14 human clinical trials, and over 10 years of research. It won the 2021 Frost & Sullivan North American Immune Health Ingredient and New Product Innovation Award, and it is distributed by Kyowa Hakko, an international ingredients manufacturer whose primary goal is to provide health solutions that support optimal health for improved quality of life.

BetterLungs® Immunity with IMMUSE™ can be purchased on the Betterbrand website at https://www.trybetterbrand.com/products/better-lungs-immunity. To learn more about IMMUSE™, go to https://immusehealth.com/.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About IMMUSE:

IMMUSE™ is a postbiotic that delivers a new, breakthrough approach to broad range immune support*. As a clinically researched immune activator* supported by 29 published studies, including 14 human trials, IMMUSE™ proactively supports the immune system through a novel method of action that activates pDC (plasmacytoid dendritic cells)*. The pDC, a rare type of immune cell, functions as the a key leader of the immune system and has been shown to activate pivotal cells such as NK, Killer-T, Helper-T, and B cells, for a more comprehensive approach to immune support*. Its unique mechanism of action, discovered by Kyowa Hakko’s parent company Kirin Holdings Co., Ltd., is opening doors for discovering postbiotics concerning immune health.

About Kyowa Hakko USA:

Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com..

About Dr. Chris Jackson, Pharm:

Dr. Chris Jackson is the founder and CEO of Betterbrand. Dr. Jackson trained at the University of Texas at Austin and had published several research projects to advance the use of rapid diagnostics in the field of infectious diseases. He served as a Combat Medic and Infantry Officer in the US Army.

About Betterbrand

Founded in 2019, Betterbrand aims for “better living through science” and designs data-backed products made from natural ingredients. Each product developed is reviewed by medical doctors in their internal Medical Advisory Committee and tested by Eurofins Scientific. Betterbrand offers premium products at affordable prices.

Media interested in setting up an interview with Karen Todd, please contact Giselle Chollett: giselle@adinnyc.com or 917.386.7116.

Share article on social media or email: